GO:0010957 negative regulation of vitamin D biosynthetic process: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010957 describes any process that decreases the rate, frequency or extent of vitamin D biosynthesis, the pathway that produces fat-soluble secosteroids such as ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) from delta-5,7 steroids.
• Vitamin D biosynthesis is a multi-step, multi-organ process: UVB-driven photoconversion in skin, hepatic 25-hydroxylation, and renal 1-alpha-hydroxylation, each of which can be negatively regulated.
• The best-characterized negative regulators are hormonal and feedback signals, including PTH, FGF23, and 1,25(OH)2D itself, which suppress CYP27B1 and stimulate catabolic enzymes such as CYP24A1.
• Dysregulated negative regulation of vitamin D biosynthesis contributes to disorders of calcium metabolism, chronic kidney disease, and inflammatory conditions such as ulcerative colitis and COVID-19.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect which genes causally restrain vitamin D biosynthetic flux in a given cell type.
• EDITGENE provides end-to-end CRISPR cell-model and library-screening services to interrogate negative regulators of vitamin D biosynthesis in physiologically relevant systems.
Description
GO:0010957, negative regulation of vitamin D biosynthetic process, is a Gene Ontology biological_process term that captures any mechanism which decreases the rate, frequency or extent of vitamin D biosynthesis. Vitamin D biosynthesis is the set of chemical reactions and pathways that generate vitamin D compounds, a group of related fat-soluble secosteroids derived from delta-5,7 steroids, including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which play a central role in calcium metabolism. Because vitamin D status influences skeletal health, immune function and multiple chronic diseases, understanding how this biosynthetic process is restrained is of broad biomedical importance. The pathway is distributed across tissues: 7-dehydrocholesterol in skin is photoconverted to previtamin D3, which isomerizes to cholecalciferol; the liver then performs 25-hydroxylation to form 25-hydroxyvitamin D, the major circulating metabolite; and the kidney performs 1-alpha-hydroxylation to generate the active hormone 1,25-dihydroxyvitamin D. Negative regulation can act at any of these steps, either by reducing the availability of substrates, by suppressing the hydroxylase enzymes that drive activation, or by accelerating catabolism of the active hormone. For researchers, GO:0010957 provides a formal framework to annotate genes and pathways that limit vitamin D production. Such annotations are increasingly relevant to studies of calcium homeostasis, renal and hepatic disease, inflammation, and cancer biology, where altered vitamin D biosynthesis or catabolism has been observed. This article summarizes the definition, mechanism, key genes, disease links and experimental strategies for studying negative regulation of vitamin D biosynthetic process.
negative regulation of vitamin D biosynthetic process At A Glance
| GO ID | GO:0010957 |
|---|---|
| GO term | negative regulation of vitamin D biosynthetic process |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that decreases the rate, frequency or extent of a vitamin D biosynthetic process, the chemical reactions and pathways resulting in the formation of vitamin D, a group of fat-soluble compounds derived from delta-5,7 steroids that play a central role in calcium metabolism. |
| Major function | Restrains the production of vitamin D metabolites, including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), thereby modulating calcium and phosphate homeostasis. |
| Representative regulators | PTH, FGF23, 1,25(OH)2D feedback, CYP24A1, CYP27B1 suppression. |
| Associated tissues | Skin, liver, kidney, and immune cells. |
| Disease relevance | Disorders of calcium metabolism, chronic kidney disease, inflammatory bowel disease, and COVID-19. |
What Is GO:0010957?
In our own words, GO:0010957 refers to any biological process that reduces the rate, frequency or extent of vitamin D biosynthesis. It does not describe the biosynthetic reactions themselves, but rather the regulatory inputs that slow or suppress them. These inputs may include hormonal signals, feedback inhibition by the vitamin D product, changes in enzyme abundance or activity, or competition for substrates. The term is therefore a negative regulatory node that sits upstream of, or within, the vitamin D biosynthetic pathway and modulates the output of active vitamin D.
Why Is negative regulation of vitamin D biosynthetic process Important in Cell Biology?
Negative regulation of vitamin D biosynthetic process is important because it sets the upper limit on circulating active vitamin D and prevents excessive calcium absorption. When this negative regulation is too weak, hypercalcemia and hypercalciuria can ensue; when it is too strong, vitamin D deficiency and its skeletal and extraskeletal consequences may develop. The term also provides a mechanistic lens for interpreting how hormones such as PTH and FGF23, and feedback by 1,25-dihydroxyvitamin D itself, coordinate vitamin D production with systemic calcium demand. In disease contexts ranging from ulcerative colitis to COVID-19, altered vitamin D metabolism has been linked to inflammation and clinical severity, making the regulatory arm of this pathway a legitimate therapeutic and biomarker target.
• Maintains calcium and phosphate homeostasis by preventing overproduction of active vitamin D.
• Provides feedback control through 1,25(OH)2D-mediated suppression of CYP27B1 and induction of CYP24A1.
• Integrates hormonal signals such as PTH and FGF23 with vitamin D biosynthetic output.
• Contributes to the pathophysiology of chronic kidney disease, where reduced renal 1-alpha-hydroxylation limits active vitamin D.
• Modulates immune and inflammatory responses, as seen in ulcerative colitis and COVID-19 studies.
• Influences liver inflammation and fibrosis through vitamin D-related signaling in ductular cells.
• Serves as a target for pharmacological and genetic interventions aimed at raising or lowering vitamin D status.
• Provides a conceptual framework for annotating genes that restrain vitamin D biosynthesis in genomic and transcriptomic studies.
What Happens During negative regulation of vitamin D biosynthetic process?
Suppression of cutaneous vitamin D3 production
In simple terms: The skin makes vitamin D3 when sunlight hits a cholesterol-like molecule, and this step can be slowed by factors such as pigmentation, aging, or reduced UVB exposure.
The first step in vitamin D biosynthesis is the UVB-dependent photoconversion of 7-dehydrocholesterol to previtamin D3, which then isomerizes to cholecalciferol (vitamin D3) in the skin. Negative regulation at this stage includes reduced substrate availability, decreased UVB penetration, and increased melanin content, all of which lower the rate of cholecalciferol formation. Because this step is non-enzymatic and light-dependent, its negative regulation is primarily physical and environmental rather than transcriptional.
Inhibition of hepatic 25-hydroxylation
In simple terms: The liver attaches a hydroxyl group to vitamin D3 to make 25-hydroxyvitamin D, the form measured in blood tests, and this step can be slowed by liver dysfunction or by feedback signals.
Cholecalciferol is transported to the liver, where CYP2R1 and related enzymes catalyze 25-hydroxylation to form 25-hydroxyvitamin D, the major circulating metabolite. Negative regulation of this step can occur through reduced hepatic enzyme activity, competition with other CYP substrates, or feedback inhibition by downstream metabolites. Because 25-hydroxyvitamin D is the clinical biomarker of vitamin D status, any process that decreases its formation directly lowers measured vitamin D levels.
Inhibition of renal 1-alpha-hydroxylation
In simple terms: The kidney converts 25-hydroxyvitamin D into the active hormone, and this conversion is tightly controlled by hormones like PTH and FGF23.
In the proximal tubule, CYP27B1 catalyzes 1-alpha-hydroxylation of 25-hydroxyvitamin D to produce 1,25-dihydroxyvitamin D, the biologically active hormone. Negative regulation of this step is mediated by FGF23, which suppresses CYP27B1 expression, and by 1,25-dihydroxyvitamin D itself through negative feedback. PTH stimulates CYP27B1, so factors that reduce PTH signaling indirectly decrease 1-alpha-hydroxylation. This step is the principal control point for active vitamin D production.
Induction of catabolic enzymes
In simple terms: Enzymes like CYP24A1 break down active vitamin D, and when they are turned on, they reduce the amount of vitamin D available to the body.
CYP24A1 initiates the catabolism of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, converting them to less active metabolites. Induction of CYP24A1 by 1,25-dihydroxyvitamin D constitutes a negative feedback loop that limits the accumulation of active hormone. FGF23 also induces CYP24A1, further reducing vitamin D availability. Thus, catabolic enzyme induction is a major mechanism of negative regulation of vitamin D biosynthetic process.
Feedback by 1,25-dihydroxyvitamin D
In simple terms: The active form of vitamin D can turn down its own production, acting like a thermostat to prevent excessive levels.
1,25-dihydroxyvitamin D binds the vitamin D receptor (VDR) and regulates transcription of genes involved in its own metabolism, including suppression of CYP27B1 and induction of CYP24A1. This negative feedback loop is a canonical example of negative regulation of vitamin D biosynthetic process. Disruption of this feedback can lead to excessive or insufficient active vitamin D, contributing to disorders of calcium metabolism.
Key Genes Involved in GO:0010957 negative regulation of vitamin D biosynthetic process
The following genes and proteins are central to the negative regulation of vitamin D biosynthetic process, based on their roles in vitamin D metabolism, transport, and feedback control.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP27B1 | Catalyzes 1-alpha-hydroxylation of 25-hydroxyvitamin D; its suppression reduces active vitamin D synthesis | Target for studying renal and extrarenal vitamin D activation |
| CYP24A1 | Initiates catabolism of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D; induced by active vitamin D and FGF23 | Key negative regulator and biomarker of vitamin D catabolism |
| CYP2R1 | Hepatic 25-hydroxylase that produces 25-hydroxyvitamin D | Determines circulating vitamin D status |
| VDR | Mediates 1,25-dihydroxyvitamin D signaling and feedback suppression of CYP27B1 | Central to vitamin D endocrine feedback |
| FGF23 | Suppresses CYP27B1 and induces CYP24A1, reducing active vitamin D | Links phosphate metabolism to vitamin D regulation |
| PTH | Stimulates CYP27B1; reduced PTH signaling lowers active vitamin D | Hormonal regulator of calcium and vitamin D |
| GC | Vitamin D binding protein; affects transport and availability of vitamin D metabolites | Modulates bioavailability of vitamin D |
| CYP3A4 | Alternative vitamin D 25-hydroxylase and catabolic enzyme | Contributes to vitamin D metabolite clearance |
| CYP27A1 | Mitochondrial 25-hydroxylase with roles in bile acid and vitamin D metabolism | Potential alternative activation pathway |
| ACSL4 | Lipid metabolism enzyme linked to ferroptosis; vitamin D attenuates colitis by inhibiting ACSL4 | Connects vitamin D biology to ferroptosis and inflammation |
| TXNIP | Thioredoxin-interacting protein upregulated by vitamin D supplementation in ductular cells | Mediates vitamin D effects on liver inflammation and fibrosis |
| Meflin | Cancer-associated fibroblast marker that inhibits pancreatic carcinogenesis | Example of stromal regulation relevant to vitamin D-related tumor biology |
| AHR | Aryl hydrocarbon receptor with distinct regulation relative to VDR in COVID-19 | Links vitamin D pathway to immune and environmental signaling |
| KL | Klotho, a co-receptor for FGF23 signaling | Modulates FGF23-mediated suppression of vitamin D activation |
| SLC34A1 | Sodium-phosphate cotransporter regulated by vitamin D and PTH | Integrates vitamin D with phosphate homeostasis |
| CASR | Calcium-sensing receptor that regulates PTH secretion | Indirectly controls vitamin D activation |
| RXR | Retinoid X receptor, heterodimer partner of VDR | Required for vitamin D receptor signaling |
| NR4A1 | Nuclear receptor implicated in feedback regulation of vitamin D metabolism | Potential transcriptional regulator of vitamin D pathway |
How Is negative regulation of vitamin D biosynthetic process Regulated?
Negative regulation of vitamin D biosynthetic process is itself regulated by a network of hormonal and metabolic inputs. PTH stimulates CYP27B1 and thus increases active vitamin D, so factors that suppress PTH, such as elevated calcium or FGF23, indirectly reduce vitamin D activation. FGF23, acting through FGFR1 and Klotho, suppresses CYP27B1 and induces CYP24A1, providing a powerful brake on active vitamin D production. 1,25-dihydroxyvitamin D feedback inhibits its own synthesis by suppressing CYP27B1 and inducing CYP24A1, forming a classic endocrine feedback loop. In inflammatory states, cytokines and immune signals can modulate vitamin D metabolism, as observed in ulcerative colitis and COVID-19 studies. Vitamin D supplementation itself can upregulate TXNIP in ductular cells, illustrating tissue-specific regulatory responses.
negative regulation of vitamin D biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP27B1 | Chronic kidney disease, rickets | Renal proximal tubule cell knockout of CYP27B1 |
| CYP24A1 | Hypercalcemia, idiopathic infantile hypercalcemia | Hepatic or renal CYP24A1 overexpression and knockout models |
| VDR | Vitamin D-dependent rickets, immune dysfunction | VDR knockout cell lines and knock-in reporter models |
| ACSL4 | Ulcerative colitis, ferroptosis | Intestinal epithelial ACSL4 knockout with vitamin D treatment |
| TXNIP | Liver inflammation and fibrosis | Ductular cell TXNIP overexpression and knockout |
Disorders of calcium metabolism
Inadequate or excessive negative regulation of vitamin D biosynthesis can lead to abnormal calcium homeostasis. When negative regulation is insufficient, excessive active vitamin D may cause hypercalcemia and hypercalciuria; when it is excessive, vitamin D deficiency and hypocalcemia may develop. These imbalances underlie conditions such as rickets, osteomalacia, and secondary hyperparathyroidism in chronic kidney disease.
Chronic kidney disease
In chronic kidney disease, loss of renal 1-alpha-hydroxylase activity and increased FGF23 signaling contribute to reduced active vitamin D production. The resulting negative regulation of vitamin D biosynthesis exacerbates mineral and bone disorders, making this pathway a therapeutic target.
Inflammatory bowel disease and ulcerative colitis
Vitamin D attenuates ulcerative colitis by inhibiting ACSL4-mediated ferroptosis, indicating that vitamin D biosynthetic output and its negative regulation influence intestinal inflammation. Dysregulated vitamin D metabolism may therefore contribute to inflammatory bowel disease pathogenesis.
COVID-19 and immune regulation
The vitamin D receptor and aryl hydrocarbon receptor show distinct regulation in COVID-19, suggesting that vitamin D pathway activity, including its negative regulation, may influence immune responses to infection. Vitamin D status has been associated with clinical outcomes, although causal relationships remain under investigation.
From negative regulation of vitamin D biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase vitamin D biosynthetic flux? | CRISPR knockout in renal or hepatic cell lines |
| Does a specific point mutation alter enzyme activity? | CRISPR point-mutation knock-in of catalytic residues in CYP27B1 or CYP24A1 |
| Does a regulatory variant affect CYP27B1 expression? | Knock-in of promoter or enhancer variants with reporter tagging |
| Where is a negative regulator expressed in tissue? | Tagged knock-in of endogenous locus with fluorescent or epitope tag |
| Does overexpression of a catabolic enzyme reduce vitamin D levels? | Stable overexpression of CYP24A1 in vitamin D-producing cells |
| Which genes causally restrain vitamin D biosynthesis? | Genome-wide CRISPR library screening in a vitamin D reporter system |
How to Study the negative regulation of vitamin D biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on vitamin D biosynthesis | Testing candidate negative regulators |
| CRISPR point mutation | Effect of specific amino acid changes on enzyme activity | Dissecting catalytic or regulatory residues |
| RNA-seq | Transcriptional changes in vitamin D pathway genes | Identifying feedback and crosstalk |
| Proteomics | Protein abundance and post-translational modifications | Mapping regulatory networks |
| Mass spectrometry | Levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D | Functional readout of biosynthetic flux |
| Reporter assays | Promoter activity of CYP27B1 or CYP24A1 | Screening for regulators |
| Immunofluorescence | Subcellular localization of vitamin D enzymes | Validating trafficking and assembly |
| CRISPR library screening | Genome-wide identification of negative regulators | Discovery of novel pathway components |
CRISPR knockout and point-mutation models
CRISPR-Cas9 knockout of candidate negative regulators such as CYP24A1 or FGF23 pathway components allows direct testing of their role in vitamin D biosynthesis. Point-mutation knock-in can be used to dissect catalytic residues or regulatory phosphorylation sites in enzymes like CYP27B1.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify expression changes in vitamin D pathway genes following genetic or pharmacological perturbation, revealing feedback loops involving VDR, CYP24A1, and CYP27B1. These approaches help identify novel negative regulators of vitamin D biosynthesis.
Metabolite quantification
Mass spectrometry-based measurement of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D is essential to determine whether a genetic perturbation alters vitamin D biosynthetic flux. Such measurements provide the functional readout for negative regulation.
Reporter and imaging assays
Luciferase or fluorescent reporters driven by CYP27B1 or CYP24A1 promoters enable live-cell monitoring of negative regulation in response to hormones and inflammatory signals. Imaging of tagged enzymes can reveal subcellular localization and trafficking.
How CRISPR Can Be Used to Study GO:0010957 negative regulation of vitamin D biosynthetic process
Knockout
CRISPR knockout of genes such as CYP24A1, FGF23, or VDR can reveal their contribution to negative regulation of vitamin D biosynthesis. For example, CYP24A1 knockout is expected to increase active vitamin D levels, while FGF23 knockout may enhance CYP27B1 expression.
Point Mutation
Point-mutation knock-in allows precise interrogation of catalytic residues in CYP27B1 or CYP24A1, or of phosphorylation sites in regulatory proteins. Such models help distinguish loss-of-function from gain-of-function mechanisms in vitamin D metabolism.
Knock-in
Knock-in of reporter tags or regulatory variants at endogenous loci enables tracking of vitamin D enzyme expression and localization. This is useful for studying feedback regulation by 1,25-dihydroxyvitamin D and FGF23.
Overexpression
Overexpression of catabolic enzymes like CYP24A1 or of negative regulators such as FGF23 can suppress vitamin D biosynthesis, providing a gain-of-function counterpart to knockout studies.
How EDITGENE Supports negative regulation of vitamin D biosynthetic process Research
Researchers studying negative regulation of vitamin D biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in restraining vitamin D production, or whether its association is merely correlative. CRISPR-based cell models provide the gold-standard approach to establish causality by introducing precise genetic perturbations and measuring downstream vitamin D metabolites.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of vitamin D biosynthetic process research.
Frequently Asked Questions About negative regulation of vitamin D biosynthetic process
What is GO:0010957 negative regulation of vitamin D biosynthetic process?
GO:0010957 is a Gene Ontology biological_process term describing any process that decreases the rate, frequency or extent of vitamin D biosynthesis, the pathway producing fat-soluble secosteroids such as vitamin D2 and vitamin D3.
What genes are involved in negative regulation of vitamin D biosynthetic process?
Key genes include CYP24A1, CYP27B1, CYP2R1, VDR, FGF23, PTH, and GC, which together control vitamin D activation and catabolism.
How is vitamin D biosynthesis negatively regulated?
Negative regulation occurs through suppression of cutaneous production, inhibition of hepatic 25-hydroxylation, inhibition of renal 1-alpha-hydroxylation, induction of catabolic enzymes like CYP24A1, and feedback by 1,25-dihydroxyvitamin D.
What is the role of CYP24A1 in vitamin D regulation?
CYP24A1 initiates catabolism of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and its induction by active vitamin D and FGF23 provides a major negative feedback mechanism.
How does FGF23 affect vitamin D biosynthesis?
FGF23 suppresses CYP27B1 and induces CYP24A1, thereby reducing active vitamin D production and linking phosphate metabolism to vitamin D regulation.
What diseases are linked to dysregulated vitamin D biosynthesis?
Disorders of calcium metabolism, chronic kidney disease, ulcerative colitis, and COVID-19 have been associated with altered vitamin D metabolism and its regulation.
How can CRISPR be used to study negative regulation of vitamin D biosynthesis?
CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate genes in vitamin D-producing cells, with metabolite measurements as readout.
What cell models are suitable for studying vitamin D biosynthesis?
Renal proximal tubule cells, hepatocytes, keratinocytes, and intestinal epithelial cells are commonly used, depending on the step of the pathway being studied.
What is the clinical biomarker for vitamin D status?
25-hydroxyvitamin D is the major circulating metabolite and the standard clinical biomarker of vitamin D status.
Does vitamin D supplementation affect negative regulation of its own biosynthesis?
Yes, vitamin D supplementation can upregulate genes such as TXNIP in ductular cells and can feedback on CYP27B1 and CYP24A1, illustrating tissue-specific regulatory responses.
Conclusion
GO:0010957 negative regulation of vitamin D biosynthetic process provides a precise ontological framework for understanding how the body restrains production of vitamin D metabolites. The pathway is controlled by hormonal signals, feedback loops, and catabolic enzymes, with CYP24A1, CYP27B1, FGF23, PTH, and VDR playing central roles. Dysregulation of this process is implicated in calcium disorders, kidney disease, inflammatory conditions, and immune responses. CRISPR-based cell models are indispensable for establishing causality and for discovering new regulators of vitamin D biosynthesis. By combining knockout, point-mutation, knock-in, overexpression, and library-screening approaches with metabolite quantification, researchers can dissect this pathway with unprecedented precision. EDITGENE offers comprehensive services to support such studies from design to data analysis.
References
- 1. Khundmiri SJ et al.. 2016. PTH and Vitamin D.. Compr Physiol 6(2):561-601 PMID: 27065162
- 2. Peacock M. 2010. Calcium metabolism in health and disease.. Clin J Am Soc Nephrol 5 Suppl 1:S23-30 PMID: 20089499
- 3. Gao S et al.. 2023. Vitamin D Attenuates Ulcerative Colitis by Inhibiting ACSL4-Mediated Ferroptosis.. Nutrients 15(22) PMID: 38004239
- 4. Mizutani Y et al.. 2019. Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis.. Cancer Res 79(20):5367-5381 PMID: 31439548
- 5. Lips P. 2006. Vitamin D physiology.. Prog Biophys Mol Biol 92(1):4-8 PMID: 16563471
- 7. Robak O et al.. 2024. The Distinct Regulation of the Vitamin D and Aryl Hydrocarbon Receptors in COVID-19.. Nutrients 16(5) PMID: 38474725
- 8. Baek EB et al.. 2025. Vitamin D supplementation ameliorates ductular reaction, liver inflammation and fibrosis in mice by upregulating TXNIP in ductular cells.. Nat Commun 16(1):4420 PMID: 40360509
